NEW YORK – The UK's National Institute for Health and Care Excellence published a draft guidance on Thursday recommending Merck's PD-1 inhibitor pembrolizumab (Keytruda) combined with pemetrexed and platinum-based chemotherapy as a first-line treatment for advanced non-small cell lung cancer patients regardless of PD-L1 expression status.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.